Provided by Tiger Trade Technology Pte. Ltd.

ImageneBio, Inc.

6.91
+0.06000.88%
Post-market: 6.910.00000.00%16:10 EST
Volume:18.47K
Turnover:129.92K
Market Cap:77.27M
PE:-0.79
High:7.21
Open:6.95
Low:6.87
Close:6.85
52wk High:18.70
52wk Low:5.70
Shares:11.18M
Float Shares:6.20M
Volume Ratio:0.44
T/O Rate:0.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.7700
EPS(LYR):-0.1236
ROE:--
ROA:--
PB:0.55
PE(LYR):-55.90

Loading ...

Company Profile

Company Name:
ImageneBio, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
12526 High Bluff Drive,Suite 345,San Diego,California,United States
Zip Code:
92130
Fax:
- -
Introduction:
Ikena Oncology, Inc. operates as an oncology company that develops precision medicines to biomarker-defined patients with specific unmet needs in the United States. Its lead oncology product candidate is IK-930, a paralog selective inhibitor of the transcriptional enhanced associate domain, a transcription factor in the Hippo signaling pathway. It also develops IK-595, designed to trap MEK and RAF for inhibiting RAS signals than existing inhibitors; and IK-175, a monotherapy and in combination with nivolumab in patients with advanced or metastatic solid tumors, including urothelial carcinomas. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Directors

Name
Position
Kristin Yarema
Chief Executive Officer and Director and Interim Principal Financial Officer
David Bonita
Lead Independent Director
Jonathan Jian Wang
Chair of the Board
Joseph P. Slattery
Director
Otello Stampacchia
Director
Stephen Hui Wang
Director
Weiguo Su
Director

Shareholders

Name
Position
Kristin Yarema
Chief Executive Officer and Director and Interim Principal Financial Officer